Skip to content

Study · Not a test of the peptide alone · 2009

1 result

Phosphodiesterase inhibitor-dependent inverse agonism of agouti-related protein on melanocortin 4 receptor in sea bass (Dicentrarchus labrax).

Sánchez E, Rubio VC, Thompson D, Metz J, Flik G, Millhauser GL, Cerdá-Reverter JM

American journal of physiology. Regulatory, integrative and comparative physiology18 Feb 2009Cited by 54 (Europe PMC)

PMID19225141 (opens in a new tab)PMCIDPMC2689838 (opens in a new tab)DOI10.1152/ajpregu.90948.2008 (opens in a new tab)PepBankPUB-19225141
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    AGRP acted as a competitive antagonist and reduced MTII-induced cAMP production at sea bass MC4R; MTII served as the challenge agonist.

    In plain wordsIn lab tests, AGRP reduced the cAMP response that MTII caused at the sea bass MC4R receptor.

    Peptide
    Melanotan II
    Outcome
    DecreaseAGRP effect on MTII-induced cAMP production at sea bass MC4R
    Study

    sea bass (Dicentrarchus labrax)n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    We demonstrate that AGRP acts as competitive antagonist and reduces MTII-induced cAMP production.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.